500P - Clinical outcome of ifosfamide in combination with carboplatin in small cell lung cancer: Results from third- or further- line chemotherapy

Abstract

Background: The number of available regimens which can be used in relapsed small-cell lung cancer (SCLC) is small and the data of the regimens is lack than those of non-small cell lung cancer. The goal of the present study is to evaluate the clinical outcome of ifosfamide and carboplatin (IC) regimen for third- or further-line chemotherapy in SCLC patients. Methods: A retrospective analysis was conducted of all patients who received combination chemotherapy with IC regimenbetween 2011 and 2015 for SCLC. The data included baseline demographics, chemotherapy-related toxicities, therapeutic regimens that used and survival period. Results: A total of 12 patients were administered IC regimen. All of the IC regimens were used in third- or further-line chemotherapy and 9 (75%) of cases were fourth-line therapy. Of the 37 chemotherapy-related toxicity events, 27 (73%) were hematologic toxicities and thrombocytopenia (n = 10 (27%)) was reported most frequently. The median overall survival (OS) after IC administration was 3.5 months. Patients with positive change of body mass index (BMI) before IC administration (p = 0.071), without multiple metastases at start of IC regimen (p = 0.001), refractory relapse after first line treatment (p = 0.082), partial response or stable disease to the IC treatment (p = 0.007) showed longer duration of OS.Table: 500P Patient characteristics (n = 12) at diagnosis and point of IC administrationParameterValueMale10 (83.3%)Pre-IC age: median (range)59 (43-67) yearsPre-IC ECOG00 (0%)14 (33.3%)27 (58.3%)31 (8.3%)40 (0%)SMK: median (range)40 (0-80) packyearsBMI: median (range)at diagnosis23.31 (16.93-31.75) kg/m2pre-IC23.07 (18.58-29.79) kg/m2Pre-IC albumiin: median (range)3.75 (3.3-4.1) mg/dLPre-IC LDH: median (range)510.50 (367-1245) U/LPre-IC Sodium: median (range)135.70 (125.60- 138.50) mEq/LPre-IC Hb: median (range)11.30 (9.3-13.4) g/dLTNM staging at diagnosisIIIB2 (16.7%)IV10 (83.3%)VALG staging at diagnosisLD2 (16.7%)ED10 (83.3%)Multiple metastases at start of IC regimenNo5 (41.7%)Yes7 (58.3%)Type of relapase after 1st line treatmentSensitive6 (50%)Refractory6 (50%)Response to IC regimenCR0 (0%)PR2 (16.7%)SD1 (8.3%)PD9 (75%)Initial treatment methodCCRTx2 (16.7%)CTx10 (83.3%)Line of therapy that IC regimen used3rd2 (16.7%)4th9 (75%)5th1 (8.3%) Open table in a new tab Conclusions: The IC regimen is a reasonable therapeutic arm for relapsed SCLC. Legal entity responsible for the study: Myoungrin Park Funding: None Disclosure: All authors have declared no conflicts of interest.